Bruker Unveils New Mass-Spectrometry Products, Boosts CALID

Using a smartphone to calculate data

Keeping in line with the company's product expansion strategy, Bruker CorporationBRKR recently introduced a broad line of mass spectrometry products and workflows at the ASMS (American Society for Mass Spectrometry) conference. The company claims these products to act as breakthroughs in life-science research, in clinical research and large-cohort validations in phenomics and proteomics, in biopharma applications and in applied toxicology and forensics markets.

The Launches

The mass spectrometry products launched by the company are as follows:

The company has introduced scimaXTM Magnetic Resonance Mass Spectrometer (MRMS),which comes under Phenomics and Proteomics Innovations. The product is designed to enable high-throughput phenomics by extreme resolution MRMS. Also, the company has unveiled spotON LC-MALDI spotter for automated, wizard-based workflows within Phenomics and Proteomics Innovations category.

Within Life Sciences and Translational Mass Spectrometry Imaging, the company introduced SCiLS Lab (version 2019) with key addition of a quantitation module for mass spectrometry imaging (MSI) workflows.

Within Life-Science and Translational Research, the company introduced its fourth-generation software for metabolomics and lipidomics research, MetaboScape 4.0, powered by MRMS aXelerate. This version supports handling large studies of > 1000 samples in phenomics research. This apart, Bruker introduced a solution for non-targeted metabolomics profiling called T-ReX LC-QTOF.

Within Applied Toxicology and Forensics,the company launched an enhanced version of TargetScreener HR 3.1. This includes 600 more compounds in the field of veterinary drugs, new psychoactive substances and pesticides resulting in a database exceeding 2,800 compounds.

Mass-Spec at a Glance

Notably, Bruker's mass-spectrometry business, falling under Bruker's CALID group has demonstrated strong sales performances in recent times. This has been fuelled by a robust performance in the microbiology business and healthy results in life science research mass spectrometry.

We believe that with the newly-expanded mass-spectrometry portfolio and a focused execution within the company's two primary target markets of microbiology and diagnostics plus life science research, Bruker is going to sustain the strong momentum in mass spectrometry.

Share Price Performance

Over the past three months, shares of Bruker have outperformed its industry . The stock has gained 2.9% against the industry's 4.8% decline.

Zacks Rank & Other Stocks to Consider

Bruker currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical sector are Intuitive Surgical ISRG , Illumina, Inc ILMN and Amedisys, Inc AMED . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Amedisys holds a Zacks Rank of 2. You can see the complete list of today's Zacks #1 Rank stocks here .

Intuitive Surgical has an expected long-term earnings growth rate of 12.1%.

Illumina expects long-term earnings growth of 20%.

Amedisys has an expected long-term earnings growth rate of 17.5%.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bruker Corporation (BRKR): Free Stock Analysis Report

Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report

Illumina, Inc. (ILMN): Free Stock Analysis Report

Amedisys, Inc. (AMED): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.